Cargando…

A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome

BACKGROUND: Primary Sjögren’s syndrome (pSS) is characterized by B cell hyperactivity and elevated B-lymphocyte stimulator (BLyS). Anti-BLyS treatment (e.g., belimumab) increases peripheral memory B cells; decreases naive, activated, and plasma B cell subsets; and increases stringency on B cell sele...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mariette, Xavier, Barone, Francesca, Baldini, Chiara, Bootsma, Hendrika, Clark, Kenneth L., De Vita, Salvatore, Gardner, David H., Henderson, Robert B., Herdman, Michael, Lerang, Karoline, Mistry, Prafull, Punwaney, Raj, Seror, Raphaele, Stone, John, van Daele, Paul L.A., van Maurik, André, Wisniacki, Nicolas, Roth, David A., Tak, Paul Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2022
Materias:	Clinical Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746921/ https://www.ncbi.nlm.nih.gov/pubmed/36477362 http://dx.doi.org/10.1172/jci.insight.163030

Ejemplares similares

Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren’s syndrome: results of the BELISS study
por: Seror, Raphaèle, et al.
Publicado: (2015)

Characteristics of Sjögren’s syndrome associated with rheumatoid arthritis
por: Hassold, Nolan, et al.
Publicado: (2022)

EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide
por: Seror, Raphaèle, et al.
Publicado: (2015)

Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren’s syndrome
por: Brito-Zerón, Pilar, et al.
Publicado: (2019)

Development and preliminary validation of the Sjögren’s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren’s syndrome
por: Seror, Raphaele, et al.
Publicado: (2022)

Impact of patient ancestry on heterogeneity of Sjögren’s disease
por: Beydon, Maxime, et al.
Publicado: (2023)

A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol
por: McClure, Mark E., et al.
Publicado: (2023)

Large granular lymphocyte expansions in primary Sjögren’s syndrome: characteristics and outcomes
por: Baber, Alistair, et al.
Publicado: (2019)

Efficacy and safety of abatacept in active primary Sjögren’s syndrome: results of a phase III, randomised, placebo-controlled trial
por: Baer, Alan N, et al.
Publicado: (2021)

A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE
por: van Dam, Laura S, et al.
Publicado: (2020)

Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results
por: Kraaij, Tineke, et al.
Publicado: (2020)

High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients
por: Fabris, Martina, et al.
Publicado: (2022)

Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients
por: Capdevila, O., et al.
Publicado: (2023)

Comparison between primary Sjögren’s disease patients with high or low level of dryness
por: Kachaner, Alexandra, et al.
Publicado: (2023)

10 Years of belimumab experience: What have we learnt?
por: Levy, Roger A, et al.
Publicado: (2021)

Efficacy and safety of rituximab in peripheral ulcerative keratitis associated with rheumatoid arthritis
por: Bonnet, Isabelle, et al.
Publicado: (2021)

Population model‐based analysis of the memory B‐cell response following belimumab therapy in the treatment of systemic lupus erythematosus
por: Dimelow, Richard, et al.
Publicado: (2023)

Long‐Term Impact of Belimumab on Health‐Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment
por: Strand, Vibeke, et al.
Publicado: (2019)

T cells in primary Sjögren’s syndrome: targets for early intervention
por: Verstappen, Gwenny M, et al.
Publicado: (2019)

Imaging in Primary Sjögren’s Syndrome
por: van Ginkel, Martha S., et al.
Publicado: (2020)

Controversies on Rituximab Therapy in Sjögren Syndrome-Associated Lymphoproliferation
por: Quartuccio, Luca, et al.
Publicado: (2009)

Anti-RNP positivity in primary Sjögren’s syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement
por: Abbara, Salam, et al.
Publicado: (2019)

The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review
por: Abid, Naushad, et al.
Publicado: (2023)

The Future of Biologic Agents in the Treatment of Sjögren’s Syndrome
por: Meijer, Jiska M., et al.
Publicado: (2007)

Seasonal effect on fatigue, pain and dryness in primary Sjögren’s syndrome
por: Duret, Pierre-Marie, et al.
Publicado: (2020)

Current insights into the relationship between the gut microbiome and Sjögren’s syndrome
por: van der Meulen, Taco A., et al.
Publicado: (2020)

Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis
por: Atisha‐Fregoso, Yemil, et al.
Publicado: (2020)

Letter in reply: Crusted scabies mimicking a lupus flare after rituximab and belimumab
por: Androsov, Grigoriy, et al.
Publicado: (2021)

Revisiting the JOQUER trial: stratification of primary Sjögren’s syndrome and the clinical and interferon response to hydroxychloroquine
por: Collins, Alexis, et al.
Publicado: (2021)

Long‐Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy‐Six–Week Phase III Parent Study in the United States
por: Furie, Richard A., et al.
Publicado: (2018)

ACPA-positive primary Sjögren's syndrome: true primary or rheumatoid arthritis-associated Sjögren's syndrome?
por: Payet, J, et al.
Publicado: (2015)

Epithelial–immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis
por: Verstappen, Gwenny M., et al.
Publicado: (2021)

Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents
por: Wise, Leanna M., et al.
Publicado: (2020)

Rituximab Therapy for Primary Sjögren’s Syndrome
por: Chen, Yi Han, et al.
Publicado: (2021)

Autoantibodies in Sjögren's syndrome and its classification criteria
por: Veenbergen, Sharon, et al.
Publicado: (2021)

Clinical and Cost Burden of Primary Sjögren’s Syndrome: Descriptive Analysis Using a US Administrative Claims Database
por: Perera, Sue, et al.
Publicado: (2018)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

What have we learned from clinical trials in primary Sjögren's syndrome about pathogenesis?
por: Kallenberg, Cees GM, et al.
Publicado: (2011)

Belimumab use during pregnancy: Interim results of the belimumab pregnancy registry
por: Juliao, Patricia, et al.
Publicado: (2022)

Bcl6 for identification of germinal centres in salivary gland biopsies in primary Sjögren's syndrome
por: Nakshbandi, Uzma, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jrpo0hobg1jdk90rsc8n1cuae3